Your browser is no longer supported. Please, upgrade your browser.
Trevena, Inc.
Index- P/E- EPS (ttm)-0.32 Insider Own3.00% Shs Outstand164.51M Perf Week-7.28%
Market Cap91.88M Forward P/E- EPS next Y-0.37 Insider Trans0.00% Shs Float161.21M Perf Month-14.06%
Income-49.50M PEG- EPS next Q-0.10 Inst Own22.80% Short Float4.48% Perf Quarter-48.59%
Sales0.60M P/S153.14 EPS this Y15.20% Inst Trans-0.05% Short Ratio4.81 Perf Half Y-63.28%
Book/sh0.47 P/B1.20 EPS next Y-12.10% ROA-44.00% Target Price4.67 Perf Year-74.06%
Cash/sh- P/C- EPS next 5Y- ROE-53.50% 52W Range0.56 - 3.10 Perf YTD-2.92%
Dividend- P/FCF- EPS past 5Y27.60% ROI-28.60% 52W High-81.76% Beta2.14
Dividend %- Quick Ratio10.90 Sales past 5Y-13.30% Gross Margin-25.90% 52W Low0.98% ATR0.04
Employees25 Current Ratio11.10 Sales Q/Q-93.30% Oper. Margin- RSI (14)36.84 Volatility6.31% 6.65%
OptionableYes Debt/Eq0.00 EPS Q/Q-117.70% Profit Margin- Rel Volume0.47 Prev Close0.60
ShortableYes LT Debt/Eq0.00 EarningsNov 15 BMO Payout- Avg Volume1.50M Price0.57
Recom2.20 SMA20-9.93% SMA50-20.64% SMA200-56.64% Volume714,506 Change-5.26%
Mar-15-21Initiated Oppenheimer Perform
Sep-14-20Initiated Guggenheim Buy $5
Aug-28-20Initiated Cantor Fitzgerald Overweight $5
May-31-19Resumed H.C. Wainwright Buy
Nov-05-18Downgrade H.C. Wainwright Buy → Neutral
Oct-12-18Downgrade Needham Buy → Hold
Oct-10-18Downgrade Jefferies Buy → Hold
Nov-08-17Reiterated Needham Buy $9 → $7
Oct-16-17Downgrade Barclays Overweight → Equal Weight $15 → $2.50
Oct-12-17Reiterated H.C. Wainwright Buy $8 → $7
May-08-17Reiterated Needham Buy $11 → $9
Feb-23-17Reiterated H.C. Wainwright Buy $11 → $8
Feb-22-17Reiterated FBR & Co. Outperform $13 → $8
Feb-02-17Initiated Ladenburg Thalmann Buy $15
Jan-09-17Initiated H.C. Wainwright Buy $11
Jan-05-17Initiated Oppenheimer Outperform
May-17-16Reiterated Needham Buy $14 → $11
May-17-16Reiterated FBR Capital Outperform $13 → $16
Mar-29-16Initiated FBR Capital Outperform $16
Sep-01-15Reiterated Wedbush Outperform $15 → $20
Jan-03-22 04:05PM  
Dec-14-21 11:06AM  
Dec-13-21 07:00AM  
Nov-15-21 12:25PM  
Nov-11-21 07:00AM  
Nov-08-21 07:00AM  
Oct-25-21 03:01PM  
Oct-13-21 07:00AM  
Oct-01-21 10:40AM  
Sep-30-21 09:13AM  
Sep-17-21 07:00AM  
Sep-09-21 07:00AM  
Aug-30-21 07:00AM  
Aug-25-21 07:00AM  
Aug-20-21 09:05AM  
Aug-12-21 09:55AM  
Aug-10-21 07:00AM  
Aug-09-21 07:00AM  
Jul-26-21 07:00AM  
Jul-23-21 07:00AM  
Jul-12-21 07:00AM  
Jul-08-21 07:10AM  
Jul-07-21 07:00AM  
Jun-28-21 07:00AM  
Jun-21-21 12:00PM  
Jun-16-21 07:00AM  
Jun-09-21 07:00AM  
May-19-21 07:00AM  
May-12-21 07:00AM  
May-11-21 05:12PM  
May-06-21 10:29AM  
May-05-21 07:00AM  
Apr-29-21 07:00AM  
Apr-21-21 07:55AM  
Apr-15-21 07:30AM  
Mar-30-21 07:15AM  
Mar-18-21 07:00AM  
Mar-09-21 07:00AM  
Mar-05-21 07:00AM  
Mar-01-21 07:00AM  
Feb-22-21 07:00AM  
Jan-28-21 07:00AM  
Jan-07-21 07:00AM  
Jan-06-21 07:00AM  
Dec-10-20 08:43AM  
Dec-01-20 11:48AM  
Nov-20-20 07:00AM  
Nov-09-20 07:00AM  
Nov-05-20 05:13PM  
Oct-30-20 07:44AM  
Oct-26-20 09:22AM  
Oct-22-20 11:30AM  
Oct-05-20 07:00AM  
Sep-30-20 10:40AM  
Sep-22-20 06:45AM  
Sep-21-20 07:00AM  
Sep-18-20 09:20AM  
Sep-14-20 07:03PM  
Sep-03-20 06:20PM  
Sep-02-20 07:00AM  
Aug-28-20 10:16AM  
Aug-26-20 07:00AM  
Aug-24-20 07:00AM  
Aug-20-20 07:36AM  
Aug-18-20 08:52AM  
Aug-14-20 01:42PM  
Aug-12-20 12:20PM  
Aug-11-20 06:05PM  
Aug-10-20 05:16PM  
Aug-07-20 07:34AM  
Jul-16-20 08:56AM  
Jun-04-20 07:00PM  
Jun-03-20 09:41AM  
Jun-02-20 11:31AM  
May-22-20 11:30AM  
May-07-20 07:00AM  
May-06-20 11:30AM  
May-01-20 07:00AM  
Apr-23-20 07:00AM  
Apr-12-20 07:01AM  
Apr-07-20 09:19AM  
Mar-30-20 11:11AM  
Mar-12-20 07:01AM  
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bourdow Carrie L.President & CEOJun 28Buy1.7956,200100,5421,301,510Jun 28 05:33 PM